Clinical trial NCT02887677 - References

Diabetes Mellitus — Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.

Citation(s)

•   Abdul-Ghani MA, Norton L, DeFronzo RA
  Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep. 2012 Jun;12(3):230-8. doi: 10.1007/s11892-012-0275-6. Review.
•   Albarrán OG, Ampudia-Blasco FJ
  [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes]. Med Clin (Barc). 2013 Sep;141 Suppl 2:36-43. doi: 10.1016/S0025-7753(13)70062-9. Review. Spanish.
•   Aylsworth A, Dean Z, VanNorman C, Nkemdirim Okere A
  Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus. Ann Pharmacother. 2014 Sep;48(9):1202-1208. Epub 2014 Jun 20. Review.
•   Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J; STAR Investigators
  Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006 Dec;29(12):2592-7. Erratum in: Diabetes Care. 2007 May;30(5):1329.
•   Chao EC, Henry RR
  SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010 Jul;9(7):551-9. doi: 10.1038/nrd3180. Epub 2010 May 28. Review.
•   Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P, O'Brien E; Office versus Ambulatory Pressure Study Investigators
  Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003 Jun 12;348(24):2407-15.
•   DeFronzo RA, Davidson JA, Del Prato S
  The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012 Jan;14(1):5-14. doi: 10.1111/j.1463-1326.2011.01511.x. Review.
•   Defronzo RA
  Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009 Apr;58(4):773-95. doi: 10.2337/db09-9028.
•   Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C
  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.
•   Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF
  Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010 Oct;33(10):2217-24. doi: 10.2337/dc10-0612. Epub 2010 Jun 21.
•   Franssen PM, Imholz BP
  Evaluation of the Mobil-O-Graph new generation ABPM device using the ESH criteria. Blood Press Monit. 2010 Aug;15(4):229-31.
•   Gorostidi M, Vinyoles E, Banegas JR, de la Sierra A
  Prevalence of white-coat and masked hypertension in national and international registries. Hypertens Res. 2015 Jan;38(1):1-7. doi: 10.1038/hr.2014.149. Epub 2014 Oct 16. Review.
•   Hametner B, Wassertheurer S, Kropf J, Mayer C, Eber B, Weber T
  Oscillometric estimation of aortic pulse wave velocity: comparison with intra-aortic catheter measurements. Blood Press Monit. 2013 Jun;18(3):173-6. doi: 10.1097/MBP.0b013e3283614168.
•   Hoerger TJ, Segel JE, Gregg EW, Saaddine JB
  Is glycemic control improving in U.S. adults? Diabetes Care. 2008 Jan;31(1):81-6. Epub 2007 Oct 12.
•   Hu FB
  Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011 Jun;34(6):1249-57. doi: 10.2337/dc11-0442.
•   Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD)
  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun;35(6):1364-79. doi: 10.2337/dc12-0413. Epub 2012 Apr 19. Review. Erratum in: Diabetes Care. 2013 Feb;36(2):490.
•   Jankowski P, Kawecka-Jaszcz K, Czarnecka D, Brzozowska-Kiszka M, Styczkiewicz K, Loster M, Kloch-Badelek M, Wilinski J, Curylo AM, Dudek D; Aortic Blood Pressure and Survival Study Group
  Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension. 2008 Apr;51(4):848-55. doi: 10.1161/HYPERTENSIONAHA.107.101725. Epub 2008 Feb 11.
•   Karagiannis A, Hatzitolios AI, Athyros VG, Deligianni K, Charalambous C, Papathanakis C, Theodosiou G, Drakidis T, Chatzikaloudi V, Kamilali C, Matsiras S, Matziris A, Savopoulos C, Baltatzi M, Rudolf J, Tziomalos K, Mikhailidis DP
  Implementation of guidelines for the management of arterial hypertension. The impulsion study. Open Cardiovasc Med J. 2009 May 5;3:26-34. doi: 10.2174/1874192400903010026.
•   Karagiannis A, Tziomalos K, Anagnostis P, Gossios TD, Florentin M, Athyros VG, Mikhailidis DP
  The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis. Curr Vasc Pharmacol. 2010 Nov;8(6):792-803. Review.
•   Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A
  Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369.
•   Katsiki N, Koumaras C, Athyros VG, Karagiannis A
  Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology. 2012 Jan;63(1):9-11. doi: 10.1177/0003319711406256.
•   Koumaras C, Tzimou M, Stavrinou E, Griva T, Gossios TD, Katsiki N, Athyros VG, Mikhailidis DP, Karagiannis A
  Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics. Am J Cardiovasc Drugs. 2012 Jun 1;12(3):143-56. doi: 10.2165/11599040-000000000-00000. Review.
•   Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J
  Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013 Sep;15(9):853-62. doi: 10.1111/dom.12127. Epub 2013 Jun 5.
•   Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Non-invasive Investigation of Large Arteries
  Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006 Nov;27(21):2588-605. Epub 2006 Sep 25.
•   Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ
  Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014 Aug 15;5(4):444-70. doi: 10.4239/wjd.v5.i4.444. Review.
•   Nauck MA, Del Prato S, Durán-García S, Rohwedder K, Langkilde AM, Sugg J, Parikh SJ
  Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014 Nov;16(11):1111-20. doi: 10.1111/dom.12327. Epub 2014 Jul 10.
•   Pandey R, Kumar N, Yadav M, Nagpal R, Jain S, Yadav H
  Anti-diabetic compounds and their patent information: an update. Recent Pat Inflamm Allergy Drug Discov. 2013 Jan 1;7(1):35-48. Review.
•   Papaioannou TG, Argyris A, Protogerou AD, Vrachatis D, Nasothimiou EG, Sfikakis PP, Stergiou GS, Stefanadis CI
  Non-invasive 24 hour ambulatory monitoring of aortic wave reflection and arterial stiffness by a novel oscillometric device: the first feasibility and reproducibility study. Int J Cardiol. 2013 Oct 25;169(1):57-61. doi: 10.1016/j.ijcard.2013.08.079. Epub 2013 Sep 8.
•   Parati G, Stergiou G, O'Brien E, Asmar R, Beilin L, Bilo G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion JM, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, vanMontfrans G, Verdecchia P, Waeber B, Wang J, Zanchetti A, Zhang Y; European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability
  European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014 Jul;32(7):1359-66. doi: 10.1097/HJH.0000000000000221.
•   Protogerou AD, Argyris A, Nasothimiou E, Vrachatis D, Papaioannou TG, Tzamouranis D, Blacher J, Safar ME, Sfikakis P, Stergiou GS
  Feasibility and reproducibility of noninvasive 24-h ambulatory aortic blood pressure monitoring with a brachial cuff-based oscillometric device. Am J Hypertens. 2012 Aug;25(8):876-82. doi: 10.1038/ajh.2012.63. Epub 2012 Jun 7.
•   Protogerou AD, Smulyan H, Safar ME
  Closer to noninvasive out-of-office aortic blood pressure assessment: a time to think and act. Hypertension. 2011 Nov;58(5):765-7. doi: 10.1161/HYPERTENSIONAHA.111.177501. Epub 2011 Sep 12.
•   Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J
  Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005 Dec;54(12):3427-34.
•   Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ
  SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. doi: 10.2147/DMSO.S34416. Review.
•   Sarafidis PA, Bakris GL
  State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). 2008 Feb;10(2):130-9. Review.
•   Sarafidis PA, Georgianos PI, Karpetas A, Bikos A, Korelidou L, Tersi M, Divanis D, Tzanis G, Mavromatidis K, Liakopoulos V, Zebekakis PE, Lasaridis A, Protogerou AD
  Evaluation of a novel brachial cuff-based oscillometric method for estimating central systolic pressure in hemodialysis patients. Am J Nephrol. 2014;40(3):242-50. doi: 10.1159/000367791. Epub 2014 Oct 11.
•   Sarafidis PA, Georgianos PI, Lasaridis AN
  Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and clinical indications of diuretic compounds. Expert Opin Drug Saf. 2010 Mar;9(2):243-57. doi: 10.1517/14740330903499240. Review.
•   Shaw JE, Sicree RA, Zimmet PZ
  Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010 Jan;87(1):4-14. doi: 10.1016/j.diabres.2009.10.007. Epub 2009 Nov 6.
•   Sun YN, Zhou Y, Chen X, Che WS, Leung SW
  The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open. 2014 Apr 7;4(4):e004619. doi: 10.1136/bmjopen-2013-004619. Review.
•   Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S
  Incretins: their physiology and application in the treatment of diabetes mellitus. Diabetes Metab Res Rev. 2014 Jul;30(5):354-71. doi: 10.1002/dmrr.2501. Review.
•   Tziomalos K, Athyros VG, Karagiannis A
  Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome. Curr Pharm Des. 2014;20(39):6106-13. Review.
•   Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sarigianni M, Matthews DR, Tsapas A
  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013 Aug 20;159(4):262-74. doi: 10.7326/0003-4819-159-4-201308200-00007. Review.
•   Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C
  Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010 Aug;31(15):1865-71. doi: 10.1093/eurheartj/ehq024. Epub 2010 Mar 2. Review.
•   Vlachopoulos C, Aznaouridis K, Stefanadis C
  Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27. doi: 10.1016/j.jacc.2009.10.061. Review.
•   Vlotides G, Mertens PR
  Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease. Nephrol Dial Transplant. 2015 Aug;30(8):1272-6. doi: 10.1093/ndt/gfu299. Epub 2014 Sep 17. Review.
•   Wassertheurer S, Kropf J, Weber T, van der Giet M, Baulmann J, Ammer M, Hametner B, Mayer CC, Eber B, Magometschnigg D
  A new oscillometric method for pulse wave analysis: comparison with a common tonometric method. J Hum Hypertens. 2010 Aug;24(8):498-504. doi: 10.1038/jhh.2010.27. Epub 2010 Mar 18.
•   Weber MA, Mansfield TA, Alessi F, Iqbal N, Parikh S, Ptaszynska A
  Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. Blood Press. 2016;25(2):93-103. doi: 10.3109/08037051.2015.1116258. Epub 2015 Dec 1. Erratum in: Blood Press. 2016 Aug;25(4):x.
•   Weber MA, Mansfield TA, T'joen C, Ptaszynska A (2013) Dapagliflozin for Reduction of Blood Pressure in Diabetic Patients Inadequately Controlled With Combination Antihypertensive Regimen
  Circulation, 128; A13165.
•   Weber T, Wassertheurer S, Rammer M, Maurer E, Hametner B, Mayer CC, Kropf J, Eber B
  Validation of a brachial cuff-based method for estimating central systolic blood pressure. Hypertension. 2011 Nov;58(5):825-32. doi: 10.1161/HYPERTENSIONAHA.111.176313. Epub 2011 Sep 12.
•   Wei W, Tölle M, Zidek W, van der Giet M
  Validation of the mobil-O-Graph: 24 h-blood pressure measurement device. Blood Press Monit. 2010 Aug;15(4):225-8. doi: 10.1097/MBP.0b013e328338892f.
•   Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group
  Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012 Mar 20;156(6):405-15. doi: 10.7326/0003-4819-156-6-201203200-00003.
•   Wright EM, Turk E
  The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004 Feb;447(5):510-8. Epub 2003 May 14. Review. Erratum in: Pflugers Arch. 2004 Feb;447(5):813-5.
•   Xu X, Wang G, Zhou T, Chen L, Chen J, Shen X
  Novel approaches to drug discovery for the treatment of type 2 diabetes. Expert Opin Drug Discov. 2014 Sep;9(9):1047-58. doi: 10.1517/17460441.2014.941352. Epub 2014 Jul 23. Review.

A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes

Details for clinical trial NCT02887677